The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification
Human UDP-glucuronosyltransferase (UGT) exists as a superfamily of 22 proteins, which
are divided into 5 families and 6 subfamilies on the basis of sequence identity. Members of …
are divided into 5 families and 6 subfamilies on the basis of sequence identity. Members of …
[PDF][PDF] Phase II drug metabolizing enzymes
P Jancova, P Anzenbacher… - Biomed Pap Med Fac Univ …, 2010 - Citeseer
Background. Phase II biotransformation reactions (also 'conjugation reactions') generally
serve as a detoxifying step in drug metabolism. Phase II drug metabolising enzymes are …
serve as a detoxifying step in drug metabolism. Phase II drug metabolising enzymes are …
Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients
This review aims to provide an extensive overview of the literature on the clinical
pharmacokinetics of mycophenolate in solid organ transplantation and a briefer summary of …
pharmacokinetics of mycophenolate in solid organ transplantation and a briefer summary of …
Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons
T Shimada - Drug metabolism and pharmacokinetics, 2006 - jstage.jst.go.jp
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental carcinogens and
metabolized by a variety of xenobiotic-metabolizing enzymes such as cytochrome P450 …
metabolized by a variety of xenobiotic-metabolizing enzymes such as cytochrome P450 …
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1* 6 and* 28
H Minami, K Sai, M Saeki, Y Saito… - Pharmacogenetics …, 2007 - journals.lww.com
Objectives SN-38, an active metabolite of irinotecan, is detoxified by glucuronidation with
UGT1A isoforms, 1A1, 1A7, 1A9, and 1A10. The pharmacogenetic information on UGT1A …
UGT1A isoforms, 1A1, 1A7, 1A9, and 1A10. The pharmacogenetic information on UGT1A …
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients
E Rouits, M Boisdron-Celle, A Dumont, O Guérin… - Clinical Cancer …, 2004 - AACR
Purpose: We wanted to assess polymorphisms in the uridine diphosphoglucuronosyl
transferase 1A1 (UGT 1A1) gene: the TATA box polymorphism and UGT 1A1 G71R and …
transferase 1A1 (UGT 1A1) gene: the TATA box polymorphism and UGT 1A1 G71R and …
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan
LE Carlini, NJ Meropol, J Bever, ML Andria, T Hill… - Clinical Cancer …, 2005 - AACR
Purpose: Capecitabine and irinotecan are commonly used in the treatment of metastatic
colorectal cancer (CRC). We hypothesized that germline polymorphisms within genes …
colorectal cancer (CRC). We hypothesized that germline polymorphisms within genes …
Pharmacogenetics of irinotecan metabolism and transport: an update
NF Smith, WD Figg, A Sparreboom - Toxicology in vitro, 2006 - Elsevier
The anticancer agent irinotecan (CPT-11) is converted to SN-38, which is approximately 100
to 1000-fold more cytotoxic than the parent drug. The pharmacokinetics of irinotecan are …
to 1000-fold more cytotoxic than the parent drug. The pharmacokinetics of irinotecan are …
UDP-glucuronosyltransferases (UGTs) and their related metabolic cross-talk with internal homeostasis: A systematic review of UGT isoforms for precision medicine
UDP-glucuronosyltransferases (UGTs) are the primary phase II enzymes catalyzing the
conjugation of glucuronic acid to the xenobiotics with polar groups for facilitating their …
conjugation of glucuronic acid to the xenobiotics with polar groups for facilitating their …
Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients
Background. Mycophenolic acid (MPA) is glucuronidated by uridine diphosphate-
glucuronosyltransferases (UGTs) to its pharmacologically inactive 7-O-glucuronide …
glucuronosyltransferases (UGTs) to its pharmacologically inactive 7-O-glucuronide …